Cartesian Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotechnology company focused on cell therapy for autoimmune diseases, has announced its participation in three major healthcare investor conferences in September 2025.

The company will participate in the Cantor Global Healthcare Conference on September 4, the Morgan Stanley Healthcare Conference on September 9, and the H.C. Wainwright Global Investment Conference on September 10. All presentations will be available via webcast on the company's website.

FREDERICK, Md., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September:

• A fireside chat at the Cantor Global Healthcare Conference 2025 at 11:30 a.m. ET on Thursday, September 4, 2025
• A fireside chat at Morgan Stanley’s 23^rd Annual Healthcare Conference at 4:05 p.m. ET on Tuesday, September 9, 2025
• A presentation at the H.C. Wainwright 27^th Annual Global Investment Conference at 8:30 a.m. ET on Wednesday, September 10, 2025
  

Live webcasts of the fireside chats and presentation are expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time.

About Cartesian Therapeutics

Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.

Investor Contact

Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com

Media Contact

David Rosen
Argot Partners
david.rosen@argotpartners.com

FAQ

When is Cartesian Therapeutics (RNAC) presenting at the Cantor Global Healthcare Conference 2025?

Cartesian Therapeutics will participate in a fireside chat at 11:30 a.m. ET on Thursday, September 4, 2025.

How can investors access Cartesian Therapeutics' (RNAC) conference presentations?

Investors can access live webcasts and archived replays of the presentations in the Events section of Cartesian Therapeutics' website at www.cartesiantherapeutics.com.

What type of company is Cartesian Therapeutics (RNAC)?

Cartesian Therapeutics is a clinical-stage biotechnology company that specializes in developing cell therapy for autoimmune diseases.

Which investor conferences will Cartesian Therapeutics (RNAC) attend in September 2025?

Cartesian Therapeutics will attend three conferences: the Cantor Global Healthcare Conference, Morgan Stanley's 23rd Annual Healthcare Conference, and the H.C. Wainwright 27th Annual Global Investment Conference.